Skip to main content
Premium Trial:

Request an Annual Quote

Co-Diagnostics Expands License for CoPrimer PCR Tech With LGC

NEW YORK — Co-Diagnostics said today that it has expanded a licensing agreement for its CoPrimer PCR technology with LGC Biosearch Technologies.

CoPrimer technology uses a proprietary chemistry that attaches primers to probes with a polyethylene glycol-based linker. This method prevents the formation of primer-dimers while enabling multiplexing, according to Salt Lake City-based Co-Diagnostics. 

About a year ago, Co-Diagnostics licensed the technology to LGC for research and commercial applications in agriculture. LGC markets CoPrimer-based products for agricultural genomics under the BHQplex brand.

Under the terms of the expanded agreement, London-based LGC will now be able to use CoPrimers for additional undisclosed research applications that were not covered by the original deal.

Co-Diagnostics said that the new arrangement includes increased royalty payments from LGC, and that it stands to receive revenues from the commercialization of CoPrimer products developed by LGC customers in markets outside of agbio. Such deals, Co-Diagnostics said, will be subject to license agreements it will strike directly with those customers.

Additional terms were not disclosed.